



Final Appraisal Recommendation
Advice No: 1417 – July 2017

Cefuroxime (Aprokam®) 50 mg powder for solution for injection

Limited submission by Thea Pharmaceuticals Ltd

Recommendation of AWMSG

Cefuroxime (Aprokam®) is recommended as an option for use within NHS Wales for the antibiotic prophylaxis of postoperative endophthalmitis after cataract surgery.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2224), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

| | |
|-----------------------------------------------|--------------------------|
| Marketing authorisation holder on first issue | Thea Pharmaceuticals Ltd |
| Date of first issue | July 2017 |
| Last reviewed | August 2020 |

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 1417:
Cefuroxime (Aprokam®) 50 mg powder for solution for injection. July 2017.